癌細胞におけるアポトーシスを選択的に誘導する小分子の組み合わせ図書庫からの識別
Vitaliy Nesterenko1, Karson S Putt, Paul J Hergenrother
1Department of Chemistry, Roger Adams Laboratory, University of Illinois, Urbana, IL 61801, USA.
Journal of the American Chemical Society
|December 4, 2003
まとめ
研究者は,がん細胞のアポトーシス誘発剤を見つけるために88の化合物のライブラリを合成しました. ある化合物は,健康な白血球を傷つけることなく,がん細胞のプログラム細胞死を選択的に誘発する (U-937,HL-60).
科学分野:
- 薬用化学 薬用化学について
- 癌生物学 癌生物学について
- 分子薬理学 分子薬理学
背景:
- 癌細胞死亡の選択的誘導は,腫瘍学における重要な課題であり続けている.
- 癌細胞のアポトーシスを誘発する標的治療法の開発は,効果的な治療に不可欠です.
研究 の 目的:
- がん細胞におけるアポトーシスを選択的に誘発する化合物の88個の組み合わせライブラリを合成し,評価する.
- 癌細胞系に対する選択性が高い新規のプロアポプトシス剤を特定する.
主な方法:
- 組み合わせ化学を用いて88種類の化合物のライブラリを作成しました.
- 合成された化合物は,がん細胞系 (U-937とHL-60) でアポトーシスを誘発する能力についてスクリーニングされました.
- 選択性は,非癌性白血球に対する化合物の効果を評価することによって評価されました.
主要な成果:
- 図書室から,U-937とHL-60の癌細胞系でアポトーシスを効果的に誘発する新しい化合物が特定されました.
- この化合物は,顕著な選択性を示し,高濃度で有意な癌細胞死を誘発しました.
- 非癌性白血球では,濃度が1000μMまでであっても,実質的な毒性は観察されなかった.
結論:
- 選択的プロアポプトシス剤は,組合せ図書室のスクリーニングを通じて発見されました.
- 特定された化合物は,特定の癌のタイプに対する標的治療剤としての潜在能力を示しています.
- 作用のメカニズムと in vivo の有効性に関するさらなる調査が必要である.
さらに関連する動画
関連する概念動画
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Apoptosis
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


